You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The company withdrew its 2020 revenue guidance and said it expects to report revenues of more than $63 million in the quarter ended March 31.
The GenomeWeb Index fared better than its benchmark counterparts in March, but still fell more than 4 percent.
The funding round was led by new investor Co-Win Ventures, with additional investment by existing investors Tramway Partners, Cottonwood Technology Fund, and Sun Mountain Capital.
The deals are with institutional investors and more than 1 million American Depositary Shares will be offered at A$1.75 per ADS.
Under the guidance, only the laboratory that developed the test can perform it if the lab is CLIA-certified to perform high-complexity tests.
If the proposal is finalized, the tests will go through a less burdensome process to obtain marketing clearances.
The company will use the funds to expand its clinical genomic testing efforts into additional towns and cities in India, and accelerate its drug discovery programs.
After around six months, Genetic Signatures anticipates merging its SARS-CoV-2 test with a respiratory disease testing kit.
Color is opening a lab dedicated to SARS-CoV-2 testing and adapting its software infrastructure to enable physicians to order tests and return results.
The firm said the BARDA funding will support scale-up of a molecular test to facilitate management of the coronavirus pandemic cycle.
The panel can detect and differentiate SARS-CoV-2 and 20 other pathogens known to cause serious respiratory disease from nasopharyngeal swabs in symptomatic patients.
The Aries SARS-CoV-2 assay provides results in approximately two hours and can be run on Luminex's sample-to-answer Aries Systems.
Thermo Fisher plans to use the proceeds to pay in part for the acquisition of Qiagen, expected to close in the first half of 2021, and for general corporate purposes.
The firm delayed reporting final results due to questions of accounting irregularities but found no misconduct and made no changes to its preliminary results.
The company said the kit can provide results within 90 minutes, with sensitivity and specificity of detection reaching the level of traditional PCR methods.
Myriad has partnered with Japanese firm SRL, a subsidiary of Miraca Group, to commercialize its BRACAnalysis Diagnostic System in Japan.
The ID Now COVID-19 test is the second assay from the company to receive EUA from the FDA, following the same designation issued to the Abbott RealTime SARS CoV-2.
The NxTag CoV Extended Panel is a multiplex PCR test that uses the company's bead-based NxTag technology to detect coronavirus in nasopharyngeal swab specimens.
The $2.2 trillion economic stimulus package, aimed at bolstering the economy against the effects of the SARS-CoV-2 pandemic, has been signed into law by President Trump.
Sysmex anticipates delivering the kit to Japanese medical institutions this month for diagnosis of the SARS-CoV-2 infection.
Los Angeles brought and settled a civil enforcement action against the makers of an at-home test for SARS-CoV-2, NPR reports.
The Guardian reports that Cancer Research UK is cutting its research funding by £44 million.
Technology Review examines factors affecting SARS-CoV-2 testing turnaround times.
In PNAS this week: mapping of ancient human migrations in Europe, recurrent gene fusion in breast cancer, and more.